INJECTION SITES AND ROTATION
Where you inject matters for absorption, comfort, and the long-term health of your injection sites. Proper rotation prevents lipohypertrophy and maintains consistent absorption over weeks and months of use.
1.Subcutaneous vs intramuscular: when each is appropriate
Subcutaneous (SubQ) injection deposits the compound into the adipose (fat) tissue layer just beneath the skin. Absorption is slightly slower than intramuscular (typically 30-60 minutes to peak plasma concentration vs 15-30 minutes IM) but is significantly more comfortable, easier to self-administer at most body sites, and produces smooth, sustained absorption curves appropriate for most research peptides.
Intramuscular (IM) injection deposits the compound directly into muscle tissue, which has a denser blood supply. IM absorption is faster and more complete for some compounds. It requires a longer needle (typically 5/8 to 1 inch), is more technique-sensitive, and carries slightly higher risk of hitting a blood vessel or nerve if site anatomy is not understood.
For BPC-157, some protocols recommend injecting subcutaneously near the site of injury for a localized effect — the peptide reaches nearby tissue at higher concentrations than with a distant systemic injection. This is supported by the localized angiogenic effects BPC-157 produces. However, systemic SubQ injection (anywhere in the abdomen) also produces whole-body effects and is effective for gut health, systemic healing, and general anti-inflammatory applications.
For GH peptides (ipamorelin, CJC-1295 no DAC, GHRPs), SubQ in the abdomen is the standard. The mechanism is systemic — the peptide reaches the pituitary via circulation — so injection site proximity to the target organ does not matter. Abdominal SubQ is simply the most convenient and comfortable consistent choice.
GLP-1 agonists (semaglutide, tirzepatide, retatrutide) are always administered subcutaneously. The official sites are the abdomen, outer thigh, or back of the upper arm. Rotating between all three sites weekly is recommended in clinical practice.
2.Subcutaneous injection sites in detail
The abdomen is the most popular site for research peptide injection. The area around the navel — specifically avoiding the 2-inch radius directly around it — provides ample subcutaneous fat for most people, easy visual access for self-injection, and reliable absorption. Rotate injections around the navel in a systematic clock pattern: 12 o'clock, 3 o'clock, 6 o'clock, 9 o'clock, then shift the positions slightly to avoid exact repeat spots.
The outer thigh (lateral quadriceps) is the second most commonly used site. The central outer third of the thigh, from mid-thigh to the knee, provides accessible subcutaneous tissue. For people with very little abdominal fat, the thigh offers more tissue depth. Reach to the outer thigh with either hand; alternate legs to distribute injections.
The love handle area (lateral flanks, just above the iliac crest on the sides of the abdomen) is an often-overlooked additional site that many users find comfortable. It tends to have more subcutaneous fat than the upper abdomen and is easily accessible.
The back of the upper arm is approved for GLP-1 agonist injections in clinical use and works for other SubQ peptides when using the non-dominant arm with the other hand. Some users find this site difficult to self-inject due to angle — a syringe cap removal trick or injection helper device can facilitate it.
Sites to avoid for subcutaneous injection: the 2-inch radius directly around the navel (scar tissue from the umbilical cord and greater sensitivity), any existing scar tissue or lipohypertrophy (lumpy areas from over-used injection sites), directly over veins visible under the skin, and any site that is bruised, swollen, or irritated from a recent injection.
3.Intramuscular sites for IM injection
The ventrogluteal site is the safest IM injection site for self-administration. It avoids the major nerves and blood vessels that make the dorsogluteal (upper outer buttock) risky. Find it by placing your palm on the greater trochanter (the bony prominence on the outer hip), spreading your fingers toward the iliac crest — inject into the triangle of muscle this hand position identifies.
The vastus lateralis (outer thigh muscle) is the most accessible IM site for self-injection, visible and reachable from a seated position. The middle third of the outer thigh, between the knee and the hip, is the target zone. Pinch the skin slightly, insert at 90 degrees to the thigh surface, aspirate briefly (pull back the plunger — if blood enters the barrel, remove and reinsert), then inject slowly.
The deltoid (outer shoulder muscle) works well for small volumes (under 1 mL). The injection site is two to three finger-widths below the acromion process (the bony tip of the shoulder) on the lateral arm. This site is accessible with the opposite hand. Not appropriate for larger volumes.
The dorsogluteal (upper outer buttock, the site most people picture for 'a shot in the butt') is the least recommended for self-injection due to proximity to the sciatic nerve and the superior gluteal artery. Professional administration by another person who can identify the correct quadrant is safer here. Ventrogluteal is a safer alternative that most users can self-administer.
Aspiration (pulling back the plunger before injecting): the standard in research user communities is to aspirate briefly, particularly for IM injections in highly vascular sites. If blood enters the barrel, you have hit a blood vessel — remove the needle and reinsert at a slightly different angle. For SubQ injections, aspiration is less critical but remains a cautious practice.
4.Rotation protocol and site health
Injection site rotation is not optional — it is essential for the long-term health of your injection sites and the consistency of your protocol. Repeated injection at the same exact spot causes lipohypertrophy — a buildup of scar-like fatty tissue that is both palpable as a lump under the skin and functionally problematic because absorption from lipohypertrophic tissue is reduced and erratic.
A minimum rotation of 6-8 distinct sites for daily injectors means no single spot is used more than once per week. Map your sites: for abdominal injection, use a clock pattern around the navel with enough positions that you return to any spot no more than once per week. For multi-compound users injecting twice daily, 12+ rotation sites may be necessary.
If you discover lipohypertrophy — a hard or lumpy area under the skin at an injection site — avoid that area for 6-8 weeks minimum. Continue rotating to other sites. The lumps typically resolve with rest, though severe or long-established lipohypertrophy can be more persistent.
Signs of poor rotation: persistent small lumps under the skin, redness or tenderness that lasts more than 48 hours at any site, or a noticeable decrease in effect despite consistent dosing. The last point is the most insidious — lipohypertrophic tissue absorbs peptides inconsistently, which can make a working protocol seem to stop working.
For long-term protocols (months to years), document your injection sites and rotation pattern in your log. This creates accountability and helps identify whether site fatigue is developing before it becomes a significant problem.
Sources & Studies
Frid AH. et al., Mayo Clin Proc, 2016
Birkebaek NH. et al., Eur J Endocrinol, 2008